Tan MC, et al. - In patients with Barrett's oesophagus, researchers assessed the independent effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on the risk of oesophageal adenocarcinoma (OAC) via conducting a nested case-control study of male veterans diagnosed with Barrett's oesophagus. Among patients with Barrett's oesophagus, use of PPIs and H2RAs were correlated with lower risk of OAC.